Cowen & Co. analyst Boris Peaker maintained a Buy rating on Heron Therapeutics (HRTX) today and set a price target of $40. The company’s shares opened today at $17.53, close to its 52-week low of $16.20.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 2.9% and a 40.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Heron Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $45.20, implying a 157.8% upside from current levels. In a report issued on May 1, Northland Securities also maintained a Buy rating on the stock with a $55 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42.90 and a one-year low of $16.20. Currently, Heron Therapeutics has an average volume of 1.26M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011.
